Carbidopa

'Carbidopa is inhibitor of L-aromatic amino acid decarboxylase, also called dopa decarboxylase. Chemically Carbidopa is identified as (-)-L-a-hydrazino-3, 4-dihydroxy-a-methylhydrocinnamic acid monohydrate. It has no direct therapeutic effects of its own but rather is used only to protect levodopa and L-5-hydroxytryptophan, both of which are decarboxylated by aromatic amino acid decarboxylase. Carbidopa is used to treat symptoms of parkinson''s disease. If patient is switching from plain levodopa to combination of levodopa and it, levodopa must be discontinued for 8 hours before taking this combination drug.'

Brands
SINEMET NEUDOPA DUODOPA FORT BIDOP OBSONERV OBSONERV OBSONERV OBSONERV OBSONERV OBSONERV OBSONERV OBSONERV OBSONERV OBSONERV OBSONERV OBSONERV SINEMET EXTRA SINEMET EXTRA SINEMET EXTRA SINEMET EXTRA APTIDOPA
Adult Dose
Dose: 25 mg
Single Dose: 25 (25)
Frequency: 8 hourly
Route: PO
Instructions: Initially with levodopa 100 mg.
Neonatal
Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group
Paedriatic
Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group
Characteristics
Carbidopa also known as Methyldopa hydrazine. . It is of Synthetic origin and belongs to Propionic Acid. It belongs to L-amino acid decarboxylase inhibitor pharmacological group on the basis of mechanism of action and also classified in Antiparkinson Agents pharmacological group.The Molecular Weight of Carbidopa is 244.25. Its pKa is 2.3, 7.3.
Contraindications
Carbidopa is contraindicated in conditions like Psychosis,Narrow-angle glaucoma.
Effects
The severe or irreversible adverse effects of Carbidopa, which give rise to further complications include Postural hypotension, Psychiatric disturbances, Fluctuating disability, Dyskinesias.Carbidopa produces potentially life-threatening effects which include Neuroleptic Malignant Syndrome. which are responsible for the discontinuation of Carbidopa therapy.The symptomatic adverse reactions produced by Carbidopa are more or less tolerable and if they become severe, they can be treated symptomatically, these include Nausea, Vomiting, Palpitation, GI upset.
Indications
'Carbidopa is primarily indicated in conditions like Dopa-responsive dystonia, Parkinsonism, Parkinson''s disease, Postencephalitic parkinsonism, Symptomatic parkinsonism.'
Interactions
No data regarding the interactions of Carbidopa was found.
Interfrence
Serum tests for bilirubin, catecholamines, creatinine, glucose and uric acid. Urine Tests for Uric Acid, ketones, vinillylmandelic acid, and 5-OHindolacetic acid. Urine Tests for AminoAcids, Creatinine, Creatinine Clearance, estrogens, glucose, homogentisic acid
Risks
Drug should not be given to Paediatrics, Pregnant Mothers, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Tab Store in a well closed container, Below 40°C. Protect from Sunlight and Moisture.
Warnings
Carbidopa should be used with caution in patients with glaucoma, history of skin cancer, breathing problems, heart, kidney, liver, endocrine disease, ulcers, depression or blood disorders. This drug should be used during pregnancy only if clearly needed. Do not take this medication during lactation.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.